Changing the Game - Aiming to Cure.

Mr. Fu is the Chief Executive Office and co-founder of Attovia Therapeutics, as well as a Venture Partner at Frazier Life Sciences. Mr. Fu is a seasoned industry leader with over 25 years of executive experience in the pharmaceutical and biotech industries, including leadership roles at Zai Lab, Portola Pharmaceuticals, Bristol-Myers Squibb and Johnson & Johnson. Mr. Fu did his undergraduate studies in biology at Tsinghua University in Beijing., obtained his MS in biology from the University of Rochester and an MBA in finance and marketing from Vanderbilt University.

Dr. Chen is a partner at The Column Group, currently serving on the board of directors of Eikon Therapeutics, Remix Therapeutics and Velia, in addition to Tr1X. Previously, he was a Venture Partner at OrbiMed focusing on company creation and investing in early-stage biotech companies. In this capacity he took on interim management roles at E-Scape Bio, TranscripTx and Adicet. He also served on the board of Pionyr Immunotherapeutics and Logic Bio. Prior to that Dr. Chen was a Partner at Skyline Ventures and an entrepreneur in residence at Venrock. Dr. Chen started his career in 2002 as a founder of KAI Pharmaceuticals, which was acquired by Amgen in 2012 and led to the approval of Parsabiv in US, Europe, and Japan. He earned his BA in Biochemistry from UC Berkeley, PhD in Molecular Pharmacology from Stanford School of Medicine and MBA from Stanford Graduate School of Business.

Dr. Londei most recently was the Chief Executive Officer of Gadeta. Prior to Gadeta, he was the Chief Development Officer and Chief Medical Officer of AnaptysBio (NASDAQ: ANAB), where he played a crucial role in the company’s transition from its preclinical phase to its successful IPO, and several rounds of financing as a clinical stage biopharmaceutical company. Prior to AnaptysBio, Dr. Londei was at Bristol-Myers Squibb (BMS) where he was Therapeutic Area Head, Immunosciences and responsible for early clinical and translational research for a portfolio of immune-related therapeutics. Prior to BMS, Dr. Londei was Global Head of Autoimmunity Translational Medicine at Novartis, and Translational Science Officer for the Genomics Institute of the Novartis Research Foundation. He led the design and execution of more than 70 early-stage clinical studies at Novartis and BMS, including the development of secukinumab, canakinumab and several other biologic therapies for immune-mediated inflammatory diseases. Over the 15 years in the pharma industry, Dr. Londei and his team brought more than a dozen of new molecular entities into clinical development, six of which have since entered the market. Dr. Londei received his MD from the Faculty of Medicine at University of Bologna and has conducted post-doctoral studies at Tumor Immunology Unit, London, UK. He was a key member of the team which pioneered the development of anti-TNF therapies while at the Kennedy Institute of Rheumatology (KIR) Faculty of Medicine Imperial College, London with Professors Ravinder Maini and Marc Feldmann. Dr. Londei was Professor at the Faculty of Medicine Imperial College London, and then Professor of Autoimmunity and Gastroenterology Consultant at University College London prior to joining Novartis. He is a widely recognized world-class contributor in inflammation, and has published over 160 peer-reviewed papers in the fields of autoimmunity, self-recognition and immune modulatory checkpoints. He is a widely recognized world-class contributor in the field of inflammation and self-recognition by T lymphocytes.

Bill Lis has over 30 years of experience in the biopharmaceutical industry, at both the executive and board level. Bill currently serves as Chief Executive Officer and a member of the Board of Directors of Tr1X. Previously, he was Founding CEO and Executive Chairman at Jasper Therapeutics where he led the company’s Series A, public financing and pipeline into the clinical stage; at Eidos Therapeutics, where he served as Director until its acquisition by Bridge Bio Pharma in 2021; and at Portola Pharmaceuticals, as Chief Executive Officer and Director from 2009 to 2018 where he led its IPO and the commercial approval of Andexxa® and Bevyxxa® (Portola was acquired by Alexion in 2020). Prior to these roles, he held various executive positions at Scios (a Johnson & Johnson company), including as Senior Vice President responsible for the P&L development of Xarelto®, and various roles of responsibility at Millennium Pharmaceuticals, COR Therapeutics and Rhone Poulenc in commercial, medical affairs and business development. He served as a Bio Director for Emerging Companies and currently serves as a Director of Zai Laboratories. Mr. Lis holds a B.S. from the University of Maryland.

Jonathan serves as Tr1X's General Counsel. Prior to joining Tr1X, he was a partner at Massumi & Consoli LLP, a boutique law firm specializing in private equity M&A. Prior to MCLLP, he was a member of the Technology Companies & Life Sciences group at Goodwin Procter. Jon has represented venture-backed clients on a variety of matters, including complex domestic and cross-border transactions, financings and general corporate matters. He has a Bachelor of Arts from Harvard College and a JD from UCLA.

Dr. Kathy High is an accomplished hematologist with a longstanding interest in gene therapy for genetic disease. Most recently, Dr. High served as the President, Therapeutics of AskBio, a subsidiary of Bayer AG, and as a member of AskBio’s board of directors. Previously, Dr. High co-founded Spark Therapeutics, Inc. and from September 2014 to December 2019, she served as its President and as a member of its board of directors and served as its Head of Research & Development from September 2017 to February 2020. Dr. High also serves as a director of Incyte Corporation and CRISPR Therapeutics. From 2004 to 2014, Dr. High was a Professor at the Perelman School of Medicine at the University of Pennsylvania, an Investigator at Howard Hughes Medical Institute and the Director of the Center for Cellular and Molecular Therapeutics at the Children’s Hospital of Philadelphia. She completed a five-year term from 2000 to 2005 on the U.S. Food and Drug Administration Advisory Committee on Cell, Tissue and Gene Therapies and is a past president of the American Society of Gene & Cell Therapy. Dr. High holds an AB in chemistry from Harvard University, an MD from the University of North Carolina School of Medicine, a business certification from the University of North Carolina Business School Management Institute for Hospital Administrators and an honorary MA from The University of Pennsylvania.

Maria Grazia is the George D. Smith Professor in Stem Cell and Regenerative Medicine, Professor of Pediatrics and of Medicine, founder of the Center for Definitive and Curative Medicine, and former co-director of the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University. Dr. Roncarolo has spent her career translating discoveries in immune-mediated diseases and regenerative medicine into novel patient therapies. Dr. Roncarolo and her team were the first to discover T regulatory Type 1 cells in patients, and the first to develop curative treatments for ADA-SCID. A pediatric immunologist by training, she was instrumental in bringing novel cell and gene therapies to market including Strimvelis® and Libmeldy®. Dr Roncarolo is a co-founder of the gene-editing company Graphite Bio (NSDQ: GRPH), where she still serves as the Chair of the Scientific Advisory Board.

David has over a decade of experience founding and scaling companies at the intersection of healthcare and technology. Prior to Tr1X, David was Co-Founder and COO of Arine, a therapeutic optimization company he helped launch and scale to serve millions of patients across the US. Before that, he worked at Proteus Digital Health, one of the first techbio companies and the first in the field to obtain FDA approval for a digital medicine, Abilify MyCite®. Previously, David worked on various initiatives related to innovative healthcare payment models and the impact of the Affordable Care Act. David holds an undergraduate degree from Harvard and completed his graduate studies at the University of Cambridge.

James has 30 years of operational experience across a wide range of disciplines including research and development, manufacturing, quality operations, and marketing and sales. He most recently served as Vice President of Manufacturing at Sonoma Biotherapeutics where he created a technical operations team in support of developing cell therapies targeting autoimmune disorders. Prior to joining Sonoma, James led the clinical manufacturing division at the Fred Hutch Cancer Research Center where he had direct responsibility for the technical components of over 20 INDs and 9 DMFs involving both biologics and cell & gene therapy products. James has a Master’s in Business Administration from Rivier University and a BS in Microbiology from Michigan State University.

Dr. Flavell is Sterling Professor of Immunobiology at Yale University School of Medicine, and an Investigator of the Howard Hughes Medical Institute. He received his B.Sc. (Honors) in 1967 and Ph.D. in 1970 in biochemistry from the University of Hull, England, and performed postdoctoral work in Amsterdam (1970-72) with Piet Borst and in Zurich (1972-73) with Charles Weissmann. Before accepting his current position in 1988, Dr. Flavell was first Assistant Professor (equivalent) at the University of Amsterdam (1974-79); then Head of the Laboratory of Gene Structure and Expression at the National Institute for Medical Research, Mill Hill, London (1979-82); and subsequently President and Chief Scientific Officer of Biogen Research Corporation, Cambridge, Massachusetts (1982-88). Dr. Flavell is a fellow of the Royal Society, a member of the National Academy of Sciences as well as the National Academy of Medicine. Dr. Flavell uses transgenic and gene-targeted mice to study Innate and Adaptive immunity, T cell tolerance and activation in immunity and autoimmunity,apoptosis, and regulation of T cell differentiation.

Dr. Vijay Kuchroo is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women’s Hospital, and Co-Director of the Center for Infection and Immunity, at the Brigham Research Institutes, Boston. He is also an associate member of the Broad Institute, and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation. He is the founding Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital. His major research interests include autoimmune diseases—particularly the role of co-stimulation—the genetic basis of experimental autoimmune encephalomyelitis and multiple sclerosis, as well as cell surface molecules and regulatory factors that regulate the induction of T cell tolerance and dysfunction. His laboratory bred several transgenic mice that serve as animal models for human multiple sclerosis. The Kuchroo laboratory was also the first to describe the TIM family of genes, and identified Tim-3 as an inhibitory receptor expressed on T cells, which is now being exploited for cancer immunotherapy. He was first to describe the development of highly pathogenic Th17 cells, which have been shown to induce multiple different autoimmune diseases in humans. Dr. Kuchroo is the lead author on a paper describing the development of Th17, which is one of the most cited papers in the field of Immunology.

Dr. Luigi Naldini, is Professor of Cell and Tissue Biology and of Gene and Cell Therapy at the San Raffaele University School of Medicine and Scientific Director of the San Raffaele Telethon Institute for Gene Therapy (Milan, Italy). He has received his medical degree from the University of Turin (Italy) and his PhD from the University “La Sapienza” of Rome (Italy). For the past 25 years he has pioneered the development and the applications of lentiviral vectors for gene therapy, which have become one of the most widely used tools in biomedical research and, upon recently entering clinical testing, are providing a long-sought hope of cures for several currently untreatable and otherwise deadly human diseases. Throughout this time, he has continued to investigate new strategies to overcome the major hurdles to safe and effective gene transfer, bringing about innovative solutions that are not only being translated into new therapeutic strategies for genetic disease and cancer, but have also allowed novel insights into hematopoietic stem cell function, induction of immunological tolerance, and tumor angiogenesis. His work also contributed to advance the use of artificial nucleases for targeted genome editing in cell and gene therapy. He has published over 280 scientific papers.